Advances in Biopharmaceutical Technology in China
back to index


Chapter 2:   An Overview of Biopharmaceutical Developments in China

Dr Wu Wutong and Dr. Huang Fengjie
College of Life Science and Technology, China Pharmaceutical University
Tongjia-Xiang 24#
Nanjing, China, 210009
Tel: 0086-25-83220372 Fax: 0086-25-83220372

About the Author:
Wu Wutong:
Dr. Wu is Professor of Biochemistry and Molecular Biology, Dean of the School of Biopharmaceutics (Pharmaceutical Sciences), advisor, PhD. degree, College of Life Science and Technology, China Pharmaceutical University and has been teaching and researching biotechnology and biopharmaceutics for more than 40 years. Dr Wu has published over 300 papers and 14 special books and monographs, researched more than 10 new biological drugs (example: Elastase, FDP, recombinant asparaginase B and sHRF). He also holds a major position concurrently at the national level as Vice-Chairman of Specialist Committee of Biotechnology of the State Pharmaceutical Administration of China. In addition, Dr. Wu is Council Member of the National Gradential Committee of Degree; Council Member of the Committee for Evaluating New Drugs in China; Editor in Chief of "Pharmaceutical Biotechnology"; Chairman of Jiangsu Province Society of Biochemistry and Molecular Biology. Honors: National Specialist of Brilliant Contribution of Scientific and Technological Community; National Model Teacher; National Advanced Medical Worker of Science and Technology. E-mail:
Dr. Huang Fengjie:
College of life science and technology, China Pharmaceutical University. Education: She holds a Doctor of Biochemical Pharmacy degree, China Pharmaceutical University; Master of Veterinary Medicine, Huazhong Agricultural University; B.Sc of Animal Husbandry, Huazhong Agricultural University. Teaching and research interests. Dr. Huang teaches Microbiology and Biopharmaceutical Science in the college. Her major research activities focus on the areas of isolation and purification of natural products, drug action mechanisms, and pre-clinical studies of new biological products. Dr. Huang was involved in various research projects funded by the China Hi-Tech Research and Development Program (863 Program) and National Natural Science Foundation of China. She is also the principal researcher for the pre-clinical study on the new drug, sHRF. Dr. Huang has published more than 10 research papers in both Chinese and English journals, which include Clinical and Experimental Pharmacology and Physiology, Journal of Pharmacy and Pharmacology, and World Journal of Gastroenterology. She is also teaching Microbiology and Biopharmaceutics. E-mail:

In this chapter, we introduce the enterprise composition and industrial structure of the Chinese biopharmaceutical industry, the product composition of the modern bio-pharmaceutical industry, and the developmental characteristics, regional distribution, and ownership of Chinese biopharmaceutical enterprises. Data have shown that the Chinese biopharmaceutical industry is composed of medium- and small-scale biochemical pharmaceutical enterprises, large-scale microbiological pharmaceutical enterprises, and modern biotechnology pharmaceutical enterprises. Their products include crude drugs (e.g., medical plants), biochemical products and preparations, and biological products. Chinese bioengineering pharmaceutical enterprises are now capable of producing nearly 30 biotechnology drugs, including cytokines such as interferon, interleukin, and tumor necrosis factor, hemopoietic growth factors, growth factors, polypeptide and protein hormones, cardiovascular therapeutic agents, enzymatic preparations, recombinant vaccines, monoclonal antibody products, and gene therapy drugs. The Chinese biopharmaceutical industry is now at the stage of large-scale industrialization. Its annual sales account for around 10% of those of the national pharmaceutical industry output. There are more than 100 products under research and development, and up to 60% of them are products with independent intellectual property rights. Some leading enterprises, such as Tiantan Biologicals, Baisheng Pharmaceuticals, Star Lake Biotechnology, Fosun Group, and Jinyu Group, achieve annual sales of up to two billion yuan (US$250 million). Chinese biopharmaceutical enterprises mainly distribute in economically developed provinces, municipalities, and regions (such as Beijing, Shanghai, Shenzhen, and Changchun) in East, Central, and North China, where nearly 75% of Chinese biopharmaceutical enterprises are located. Chinese biopharmaceutical enterprises are primarily: state-ownership, collective ownership, joint-stock and cooperative ownership, joint-stock ownership, private ownership, and overseas funded and joint-venture ownership. Analyses demonstrated that overseas funded and joint-venture enterprises lead in the operational indices, followed by private and joint-stock enterprises.

back to index